

**CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)**

Applicant(s): Pitzele, et al

Docket No.

S03312

Serial No.

09/834,815

Filing Date

April 13, 2001

Examiner

Paul A. Zucker

Group Art Unit

1621

Invention: 2-Amino-3,4 Heptenoic Compounds Useful as Nitric Oxide Synthase Inhibitors

**RECEIVED**

DEC 26 2002

TECH CENTER 1600/2900

I hereby certify that this Terminal Disclaimer, Amendment B After Final, Post Card and RCE

(Identify type of correspondence)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to: The

Assistant Commissioner for Patents, Washington, D.C. 20231 on

December 13, 2002

(Date)

Philip B. Polster, II

(Typed or Printed Name of Person Mailing Correspondence)

  
(Signature of Person Mailing Correspondence)

Note: Each paper must have its own certificate of mailing.



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Pitzele et al.

GROUP ART UNIT: 1621

RECEIVED

SERIAL NO.: 09/834,815

EXAMINER: Paul A. Zucker

DEC 26 2002

FILED: April 13, 2001

DOCKET NO.: 3312


TECH CENTER 1600/2900

FOR: : 2-Amino-3, 4 Heptenoic Compounds Useful as Nitric Oxide Synthase Inhibitors

The owner\*, Pharmacia Corporation, of all right, title, and interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number 09/952,888, filed on September 15, 2002, of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

The undersigned is an attorney or agent of record.

 Date: December 13, 2002  
Philip B. Polster II, Reg. No. 43,864

\*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324.

Terminal disclaimer fee under 37 CFR 1.20(d) is included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.